|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-1-6
|
|
pubmed:abstractText |
The Wilms' tumor antigen (WT1) is overexpressed in approximately 90% of breast tumors and, thus, is a potential target antigen for the immunotherapy of breast cancer. We have tested the working hypotheses that WT1 can be immunogenic in patients with breast cancer and can stimulate CTL of sufficient avidity to kill tumor cells.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BellantuonoIlariaI,
pubmed-author:CoombesR CharlesRC,
pubmed-author:DinaRobertoR,
pubmed-author:GhaniYasmeenY,
pubmed-author:GillmoreRoopinderR,
pubmed-author:HadjiminasDimitriD,
pubmed-author:HealyVourneenV,
pubmed-author:HollerAngelikaA,
pubmed-author:KaedaJaspalJ,
pubmed-author:ParrySuzanne CSC,
pubmed-author:StaussHans JHJ,
pubmed-author:WaxmanJonathanJ,
pubmed-author:XueShao-AnSA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
34-42
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16397021-Aged,
pubmed-meshheading:16397021-Antigens, Neoplasm,
pubmed-meshheading:16397021-Cell Line, Tumor,
pubmed-meshheading:16397021-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:16397021-Female,
pubmed-meshheading:16397021-Flow Cytometry,
pubmed-meshheading:16397021-HLA-A2 Antigen,
pubmed-meshheading:16397021-Humans,
pubmed-meshheading:16397021-Lymph Nodes,
pubmed-meshheading:16397021-Middle Aged,
pubmed-meshheading:16397021-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:16397021-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:16397021-WT1 Proteins
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer.
|
|
pubmed:affiliation |
Department of Immunology and Molecular Pathology, Royal Free Hospital, London, United Knigdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
